Study on Whole-Brain Radiotherapy and Chemotherapy for Lung Cancer with Brain Metastasis
Author Information
Author(s): K Furuse, T Kamimori, M Kawahara, N Kodama, M Ogawara, S Atagi, N Naka, M Akira, K Kubota
Primary Institution: National Kinki Central Hospital for Chest Diseases, Osaka, Japan
Hypothesis
Can concurrent whole-brain radiotherapy and chemotherapy improve outcomes for patients with non-small-cell lung cancer and brain metastasis?
Conclusion
The study found that concurrent whole-brain radiotherapy and chemotherapy can be safely administered, resulting in a significant response rate and improved survival duration.
Supporting Evidence
- 75.8% of patients responded to brain lesions, including five complete responders.
- 30% of patients improved at least one grade of performance status.
- Median survival was 9.7 months with a 1-year survival rate of 40%.
Takeaway
Doctors combined radiation and chemotherapy to help patients with lung cancer that spread to the brain, and many patients got better and lived longer.
Methodology
Patients received a combination of whole-brain radiotherapy and chemotherapy with cisplatin, vindesine, and mitomycin, and their responses were evaluated over time.
Potential Biases
Potential bias due to the uncontrolled nature of the study and patient selection.
Limitations
The study was uncontrolled and had a bias for patient selection.
Participant Demographics
Patients had non-small-cell lung cancer with brain metastasis, aged less than 75 years.
Statistical Information
P-Value
0.0288
Confidence Interval
57.74-88.90%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website